U.S. Markets open in 34 mins
  • S&P Futures

    4,626.25
    +60.00 (+1.31%)
     
  • Dow Futures

    34,803.00
    +346.00 (+1.00%)
     
  • Nasdaq Futures

    16,371.50
    +221.00 (+1.37%)
     
  • Russell 2000 Futures

    2,250.90
    +53.60 (+2.44%)
     
  • Crude Oil

    68.14
    +1.96 (+2.96%)
     
  • Gold

    1,791.00
    +14.50 (+0.82%)
     
  • Silver

    22.78
    -0.03 (-0.15%)
     
  • EUR/USD

    1.1334
    -0.0005 (-0.0453%)
     
  • 10-Yr Bond

    1.4780
    +0.0350 (+2.43%)
     
  • Vix

    23.76
    +6.65 (+38.87%)
     
  • GBP/USD

    1.3334
    +0.0033 (+0.2480%)
     
  • USD/JPY

    113.1320
    -0.0480 (-0.0424%)
     
  • BTC-USD

    57,648.62
    -487.63 (-0.84%)
     
  • CMC Crypto 200

    1,475.36
    +7.43 (+0.51%)
     
  • FTSE 100

    7,159.44
    +99.99 (+1.42%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Diffusion Pharma's Trans Sodium Crocetinate Associated With Improved Outcomes In COVID-19 Patients

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients.

  • Data from the open-label study were reviewed by an independent Safety Monitoring Committee (SMC).

  • Topline results based upon analyses of primary endpoint data from the trial were announced in February, indicating that TSC was safe and well-tolerated.

  • The Company and the SMC have concluded analyses of the trial's planned secondary and exploratory endpoints, which included time to improvement in WHO ordinal scale by day 7 and through day 29, time on oxygen supplementation, and hospital length of stay.

  • It was observed that patients receiving the 1.5 mg/kg dose had improved outcomes in these secondary and exploratory endpoints compared to those receiving lower doses.

  • In addition, no patients required dialysis or developed acute kidney injury, and there were no reports of pulmonary embolism or deep vein thrombosis. One death was reported during the study of a patient who received the lowest dose, which the SMC determined to be not drug-related.

  • Diffusion has initiated a series of three short-term Oxygenation Trials in the U.S. in 2021, funded with cash-on-hand.

  • The first of these studies, the TCOM Trial, tested TSC at doses up to 2.5 mg/kg. Trial data will be completed and announced by the end of the second quarter of 2021.

  • Diffusion anticipates initiating and completing the other two short-term Oxygenation Trials in the second half of 2021, with topline results from each study available within two months of their respective completion.

  • Price Action: DFFN shares are up 0.25% at $0.68 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.